Who is ... Carolina Rosswog?

"What drives me in research is curiosity: exploring new questions and translating scientific insights into better care for children with cancer."


PD Dr. Carolina Rosswog is a pediatric oncologist, clinician-scientist, and research group leader at the Department of Pediatric Oncology and Hematology and the Department of Experimental Pediatric Oncology at University Hospital Cologne. Her research focuses on the molecular evolution of neuroblastoma, with the overarching goal of understanding the mechanisms that drive tumor initiation, progression, therapy resistance, and relapse - and translating these insights into improved risk stratification and more individualized treatment strategies for children with the disease.
 

Research Focus

A central theme of Rosswog’s research is the remarkable biological and clinical heterogeneity of neuroblastoma. While some tumors regress spontaneously or respond well to treatment, others progress aggressively, develop therapy resistance, or relapse despite intensive multimodal therapy. Understanding the molecular mechanisms underlying these divergent trajectories is essential for predicting disease course and tailoring treatment to individual patients.

Rosswog investigates how neuroblastoma evolves over time - from early tumor development through treatment to progression and relapse. By studying molecular alterations in longitudinal patient samples, her group seeks to reconstruct the evolutionary trajectories of individual tumors and determine how clonal selection and tumor heterogeneity influence treatment response.

A particular focus of her research is on telomere maintenance mechanisms. These molecular processes enable tumor cells to preserve their telomeres and maintain unlimited proliferative capacity and have emerged as powerful biomarkers of clinical outcome in neuroblastoma. Rosswog aims to translate this biological knowledge into clinically applicable tools for molecular risk stratification and precision medicine.

Selected Publications & Scientific Contributions

Rosswog’s research has contributed to a more precise molecular characterization of neuroblastoma and its evolution during the course of disease. In a first-author study published in the British Journal of Cancer in 2023, she and colleagues systematically investigated genomic alterations of the ALK oncogene in primary and relapsed neuroblastoma. The study provided insights into the occurrence and evolution of ALK alterations during disease progression and highlighted the importance of longitudinal molecular characterization for identifying potentially actionable alterations

In another study published in the Nature Genetics, she and colleagues systematically investigated highly complex genomic amplification patterns in neuroblastoma and other cancers, termed “seismic amplification”. The study provided insights into the evolution of these genomic alterations, which are associated with high-risk disease and affect oncogenes such as MYCN, CDK4 and MDM2.

Another major focus of her work is the prognostic impact of telomere maintenance mechanisms. Together with colleagues in Cologne, Rosswog contributed to the development and validation of molecular approaches that distinguish telomerase activation and alternative lengthening of telomeres from tumors without detectable telomere maintenance. This work provides an important methodological foundation for implementing telomere biology into clinically applicable molecular risk stratification.

Together, these studies illustrate the translational direction of Rosswog’s research: following molecular changes throughout the course of neuroblastoma, identifying biologically meaningful biomarkers, and determining how these insights can be used to improve diagnosis, risk assessment, and treatment.

Scientific Career & Recognition

Rosswog studied medicine at Philipps University Marburg and the University of Barcelona, with additional clinical training in Quito and Bern. Following graduation, she spent her first year working in Bern, Switzerland, before starting her clinical and scientific career in pediatric oncology and hematology and joining the Department of Experimental Pediatric Oncology at University Hospital Cologne in 2012.

Since then, she has combined patient care with experimental and translational neuroblastoma research. She was supported through a Clinician Scientist Fellowships at University Hospital Cologne, allowing her to dedicate time to clinical work and research. In 2024, she completed her habilitation and established her own research group in Experimental Pediatric Oncology.

Since 2025, Rosswog has been a Senior Consultant in Pediatric Oncology and Hematology and a fellow of the Advanced Clinician Scientist Program of the Faculty of Medicine at the University of Cologne, providing protected research time alongside her clinical responsibilities.

Her scientific work has received several distinctions, including the Kind-Philipp Award for Pediatric Oncology Research, the Erna-Brunner Award, and the Adalbert Czerny Award.

Current Research at the CMMC

In 2026, Rosswog joined the CMMC as a Career Advancement Program (CAP) Group Leader. Her CAP 46 research program, “Deciphering Neuroblastoma Evolution: Mapping Molecular Trajectories from Disease Initiation to Progression and Translating Insights into Clinical Practice,” brings together two complementary research directions: understanding clonal evolution throughout the entire course of neuroblastoma and translating molecular discoveries into improved risk stratification and precision medicine.

Her research has recently received additional support from the Marga and Walter Boll Foundation, which awarded Rosswog for the project “Telomere Maintenance Mechanisms as Prognostic and Predictive Markers in Neuroblastoma: Establishing Molecular Risk Stratification.”

The project aims to validate telomere maintenance mechanisms as biomarkers in a large patient cohort and determine whether tumors with different telomere maintenance profiles respond differently to currently available therapies.

By integrating molecular tumor evolution, biomarker development, and clinical research, Rosswog aims to advance precision medicine for neuroblastoma – improving treatment for children with high-risk disease while reducing unnecessary therapy and its potential long-term consequences for patients with more favorable disease.